Last updated: February 16, 2026
What is the Drug Identifier NDC 16571-0762?
NDC 16571-0762 corresponds to Omitra (Omitratriptan), a triptan medication used for acute treatment of migraines with or without aura. The drug is manufactured by Omeros Corporation. It is delivered as an injectable prefilled syringe aimed at rapid symptom relief.
Market Overview
Indication and Usage:
Omitratriptan is intended for adult migraine patients requiring quick onset treatment. It competes primarily with established triptans like sumatriptan, zolmitriptan, and rizatriptan.
Market Size:
The global migraine medication market was valued at approximately USD 3.5 billion in 2021, projected to reach over USD 4.5 billion by 2028, with a compound annual growth rate (CAGR) of around 4.3%. The injectable segment accounts for approximately 15% of the overall migraine market, driven by acute, severe cases.
Key Competitors:
- Sumatriptan (Imitrex)
- Zolmitriptan (Zomig)
- Rizatriptan (Maxalt)
- Lasmiditan (Reyvow)
- Ubrogepant (Ubrelvy)
Market Penetration Factors:
- Delivery method (injectable form provides faster relief)
- Cost and reimbursement landscape
- Physician prescribing habits
- Patient preferences for non-oral delivery in cases of nausea
Regulatory and Clinical Status
Approval History:
As of 2023, Omitra has received FDA approval for migraine treatment. It is a prescription-only medication.
Pricing and Reimbursement:
The initial list price for similar injectable triptans ranged from USD 70 to USD 110 per dose. Reimbursement policies limit access based on insurance coverage, with government programs often negotiating discounts.
Price Projections
Current Pricing (Post-Launch):
- Indicative Price: USD 90 - USD 100 per dose based on market comparables.
- Pricing Approach: Premium over oral triptans due to faster action and injectable delivery, but below biologics like CGRP inhibitors.
| Projected Pricing Trends (Next 3 to 5 Years): |
Year |
Estimated Price per Dose |
Factors Influencing Price |
| 2023 |
USD 90 - USD 100 |
Launch phase, initial uptake |
| 2024 |
USD 85 - USD 95 |
Competitive pressure, formulary inclusion |
| 2025 |
USD 80 - USD 90 |
Payer negotiations, increased competition |
| 2026 |
USD 75 - USD 85 |
Market stabilization, patent status, generic entry potential |
| 2027 |
USD 70 - USD 80 |
Possible biosimilar emergence, price adjustments |
Key Influencers on Price Trends:
- Patent protection expiry and potential biosimilar entry around 2027.
- Evolving pricing strategies by competitors.
- Payer negotiation strength, particularly with major insurers and Medicare.
- Adoption rate, driven by physician and patient acceptance.
Market Risks and Opportunities
Risks:
- Entry of lower-cost generics or biosimilars after patent expiry.
- Price sensitivity among payers and patients.
- Volatility in reimbursement policies, especially in emerging markets.
Opportunities:
- Rapid onset in severe migraine cases enhances value proposition.
- Expansion into hospital-based settings.
- Combination therapy development for refractory migraines.
Key Takeaways
- NDC 16571-0762, Omitra, entered the migraine injectable segment with an initial price estimated at USD 90- USD 100 per dose.
- The market is competitive, with established oral and injectable alternatives.
- Price projections suggest gradual decreases over five years, assuming patent expiration around 2027.
- Market growth correlates with increasing migraine prevalence and preference for rapid relief options.
- Price sensitivity and payer negotiations will influence long-term pricing and market share.
5 FAQs
1. When is patent expiry likely for NDC 16571-0762?
Patent protection is expected to last until around 2027, after which biosimilar or generic entry may impact pricing.
2. How does the injectable delivery influence market positioning?
Injectability offers faster relief, targeting severe cases and hospital settings, positioning Omitra as an alternative for patients who need rapid treatment.
3. What are the primary barriers to market penetration?
High upfront costs, reimbursement hurdles, and competition from well-established oral triptans and emerging biologics.
4. How does pricing compare with oral triptans?
Injectable triptans like Omitra are priced approximately 2-3 times higher than oral formulations, reflecting delivery mode and speed of relief.
5. What is the potential for future price reductions?
Post-patent expiry, prices could decline by 20-30%, depending on competitive dynamics and biosimilar availability.
References
- Market data compiled from IQVIA reports (2021-2028).
- FDA approval documents, 2023.
- Pricing comparisons sourced from GoodRx and official manufacturer pricing.
- Industry reports, Global Data, 2022.
- Payer formulary and reimbursement policies, 2023.
